|
|
|
Analysts'
Recommendation: | Buy | | 30 Days Ago: | Buy |
| | Analysts' Target: | $58 | | Analysts' Targets | | Stanford Group Company | $69 | | Hold | Thursday, June 05, 2008
| | Citigroup | $50 | | Hold | Wednesday, April 23, 2008
| | Caris & Company | $56 | | Average | Wednesday, April 23, 2008
| Edwards Lifesciences Corporation provides products and technologies designed to treat cardiovascular diseases. It focuses primarily on heart valve disease, peripheral vascular disease, and critical care technologies. The company offers tissue heart valves, such as pericardial and porcine valves, as well as repair products, including annuloplasty rings and systems, which are used to replace or repair a patient’s diseased or defective heart valve. It also provides hemodynamic monitoring equipment that is used to measure a patient’s heart function in surgical and intensive care settings; and disposable pressure transducers, and central venous access products for fluid and drug delivery. In addition, the company offers cardiac surgery system products, including cannula, intra-aortic filtration systems, and other disposable products used during cardiopulmonary bypass procedures; and vascular products that include balloon-tipped and catheter-based embolectomy products, surgical clips and clamps, and balloon-expandable and self-expanding non-coronary stents used in the treatment of peripheral vascular disease. Edwards Lifesciences distributes its products through a direct sales force and independent distributors worldwide. The company was founded in 1999 and is headquartered in Irvine, California. Edwards Lifesciences Corp. (NYSE:EW) operates independently of Baxter International Inc. as of March 31, 2000.
|
EW:
This call was made
on 07/13/08
@ $64.7
| Rating: |
$64.7 (07/13/08)
|
| Gain/Loss: |
+24.27%
in
484 days
|
| Target: |
$70.00
(+8.19%)
in > one year
|
| Allocation: |
0.1% of portfolio
|
|
